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Abstract
Background Under-reporting of adverse drug reactions (ADRs) by healthcare professionals is prevalent worldwide. Com-
munity pharmacists are the most frequently visited healthcare professional and are well placed to document ADRs as a part 
of their routine practice. Objective To measure community pharmacists’ knowledge and perspectives towards ADR reporting 
and their reporting practices. Setting Community pharmacists in the New South Wales, Queensland, Victoria and Tasmania, 
Australia. Method A survey tool consisting of 28 items was developed, piloted and validated by a panel of expert reviewers. 
The final anonymised survey was distributed online to community pharmacists. Exploratory factor analysis and Cronbach’s 
alpha were used to measure the validity and reliability of the tool, respectively. Non-parametric statistical tests were used to 
analyse knowledge, perspectives and ADR reporting practices. Main outcome measures: Knowledge, perceived importance, 
enablers and barriers to reporting ADRs. Results The survey tool showed acceptable validity and reliability. A total of 232 
respondents completed the survey. The median knowledge score was 5 out of 10 (interquartile range, 2). Less than a third 
of respondents (31.0%) reported sufficient knowledge and training on ADR reporting. Only 35.3% of pharmacists reported 
at least one ADR in the previous 12 months. Non-reporting pharmacists were more likely to report lack of time as a barrier 
(P < 0.001), conversely they were more likely to report if the practice was remunerated (P = 0.007). Conclusion Under-
reporting of ADRs by community pharmacists is highly prevalent. Initiatives to educate and train them on ADR reporting 
and simplifying the reporting process may improve reporting practices.
Keywords Adverse drug reaction · Australia · Drug safety · Pharmacist · Pharmacovigilance
Impacts on Practice
• Overcoming barriers to ADR reporting by community 
pharmacists will enhance the post-marketing surveillance 
and the safety profile of medicines.
• Suboptimal knowledge of community pharmacists in 
ADR reporting presents an opportunity for this topic to 
be included in pharmacy curriculum.
Introduction
Pharmacovigilance is defined as the “science and activi-
ties relating to the detection, assessment, understanding 
and prevention of adverse events or any other drug-related 
problem” [1]. The collection and reporting of adverse event 
information commences from the very initial stages of the 
drug development process through to the clinical trials, and 
then continuous post-marketing surveillance activities are 
conducted to obtain complete safety information for all med-
icines. Once a medicine is registered and marketed around 
the world, healthcare systems rely heavily on spontaneous 
reporting of adverse drug reactions (ADRs) to monitor the 
safety of medicines [2–4]. This helps regulatory agencies 
identify medicines that may have unidentified safety issues 
that were not observed during the clinical trials. In rare 
cases, timely identification of serious ADRs through volun-
tary reporting may save human lives as exemplified by the 
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timely withdrawal of various medicines such as cerivastatin 
and lumiracoxib [5, 6].
Currently, the responsibility for the timely collection 
and reporting of safety information mainly rests with the 
marketing authorisation holder due to mandatory reporting 
requirements from regulatory agencies [2–4]. However, as 
consumers are more likely to report ADRs to their doctors 
or pharmacists rather than to the pharmaceutical industry, 
healthcare professionals also play a significant role in ensur-
ing a robust pharmacovigilance system. Unfortunately, the 
rate of spontaneous reporting of ADRs by healthcare profes-
sionals around the world is extremely low as it is not a man-
datory requirement in most countries [7, 8]. A systematic 
review of studies conducted in the European Union showed 
that the median rate of under-reporting by healthcare profes-
sionals was 94% [9]. Furthermore, a computerized surveil-
lance study in the US showed that the rate of under-reporting 
was over 98% [10]. In Australia, the latest 2016 Therapeutic 
and Goods Administration (TGA) data show that only 4% 
of ADR reports they received were from general practi-
tioners (GPs) and 5% were from community pharmacists 
[11]. These low rates of ADR reporting are a significant 
healthcare problem and can delay regulatory actions taken 
to remove medicines with unacceptable safety profiles from 
the market. A worldwide review of 462 medicines removed 
from the market for safety reasons showed that the median 
time from drug launch to drug withdrawal was 10 years [12]. 
These delays contribute significantly to increased health-
care costs as ADRs are a major cause of hospitalisations, 
morbidity and mortality with a literature review estimating 
that ADRs contribute to 2–12% of hospital admissions in 
Australia [13, 14].
Repeated calls for mandatory ADR reporting require-
ments for healthcare professionals have been made as 
patients are more likely to discuss or potentially report a 
problem with their medications to those who initially dis-
pensed or prescribed them [15]. In Canada, the Protect-
ing Canadians from Unsafe Drugs Act was introduced in 
November 2014 to enforce mandatory reporting of serious 
ADRs by healthcare institutions [16]. In Australia, the Con-
sumers Health Forum in their submission to the 2015 San-
som review of Australian Medicines and Medical Devices 
regulations also argues for mandatory requirements for doc-
tors and pharmacists to report ADRs [15]. Furthermore, the 
TGA is introducing a black triangle scheme in 2018 to alert 
healthcare professionals and consumers that a new medicine 
is available and to request they report ADRs associated with 
that medicine [17]. These measures would enhance existing 
pharmacovigilance systems to collect more safety informa-
tion and this allows for faster action to be implemented by 
regulatory agencies if necessary. Doctors and pharmacists 
are also in the best position to report ADRs as they have 
frequent interactions with patients across all therapeutic 
areas and would therefore be an invaluable source of safety 
information.
International studies showed that healthcare professionals 
have very limited knowledge of pharmacovigilance and their 
perspectives towards ADRs play a strong role in influenc-
ing their reporting rates [18–23]. This relationship is clearly 
detailed in Suyagh et al. and Xu et al. which showed that 
perspectives of indifference, lack of remuneration, compet-
ing workplace priorities and dissatisfaction with reporting 
methods strongly impacted the ADR reporting rates [18, 
20]. There is also evidence to show a relationship between 
ADR knowledge and reporting rates, with Herdeiro et al. 
identifying a 5.9 fold increase in ADR reporting after phar-
macists were provided with a one hour educational session 
on pharmacovigilance [24]. Despite the wealth of interna-
tional literature, limited data exist on the practice of ADR 
reporting by the Australian doctors and pharmacists. The 
only two Australian studies were conducted in acute care set-
tings and as such, the perspectives of Australian community 
pharmacists on the topic of ADR reporting is lacking [25, 
26]. It is important to note that the perspectives of commu-
nity pharmacists have not been investigated to date, and it 
is vital that this gap is addressed as they are usually the first 
point of contact regarding medication related issues, as well 
as being the most frequently visited healthcare professional 
in Australia [27]. This is reinforced by the fact that over 280 
million prescriptions were dispensed through the Pharma-
ceutical Benefits Scheme over the 2016/2017 financial year 
in Australia [28].
Aim of the study
This study investigated community pharmacists’ understand-
ing of pharmacovigilance, their perspectives towards report-
ing ADRs, and their actual practice of reporting ADRs in the 
primary care setting.
Ethics approval
Approval was obtained from the Tasmanian Health and 
Medical Human Research Ethics Committee with reference 
H0016219.
Methods
Development of the survey tool
Given that there have been no studies of this type conducted 
in Australia, a pharmacovigilance survey tool was needed. 
Based on a review of the literature, we were interested in 3 
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specific domains namely, knowledge of pharmacovigilance, 
perspectives, and practices of ADR reporting. An item pool 
for each of these domains was generated based on the avail-
able literature, with the question selection based on con-
sultations with senior pharmacists from the investigators’ 
network who were known to have an interest in this topic 
and practising in various settings. The draft tool under-
went extensive testing and review by industry pharmacists 
(n = 5), community pharmacists (n = 6), hospital pharmacists 
(n = 9) and pharmacy academics (n = 5). The questions in 
the survey tool were then adjusted based on any qualita-
tive feedback provided by the respondents and the results 
of the internal consistency measure. The final survey tool 
consisted of 3 sections; the knowledge section consisted of 
10 multiple choice questions with a single correct answer, 
the perspectives section included 13 Likert item questions 
(5 point item), and the practice related questions included 4 
multi-choice questions and 1 free text question. The survey 
tool is shown as “Appendix”.
Sample size and recruitment of respondents
The Pharmacy Board of Australia’s registration statistics 
for December 2016 showed that there were 27,452 pharma-
cists with general registration in Australia [29]. Of these, 
21,429 pharmacists were practising in the eastern states of 
Australia. According to the Department of Health National 
Health Workforce Data for 2016, there was 15,257 pharma-
cists working in community pharmacy [30]. Based on a con-
fidence interval of 95% with a confidence level of +/−5%, 
we estimated a sample size of 375 pharmacists to represent 
the population [31]. Community pharmacists practising in 
New South Wales, Queensland, Victoria and Tasmania (east-
ern states of Australia) were invited to participate in this sur-
vey by email to community pharmacies, social media posts 
(Early Career Pharmacists Facebook page, Sydney Locum 
Pharmacists Facebook page, Locum Pharmacists Brisbane 
Facebook page, Pharmacist Locums—Melbourne Facebook 
page, Locum Pharmacists—Tasmania Facebook page, and 
Rural Pharmacy Locums Australia Facebook page), and the 
Australia Journal of Pharmacy discussion forum. The par-
ticipant information sheet was accessible to all respondents 
and participation was voluntary. Completion of the survey 
was considered as implied consent. A single reminder mes-
sage was posted on the above-mentioned forums at week 3 
of the study.
Statistical analysis
Statistical analyses of the main survey data were performed 
using IBM SPSS (version 24.0) with significance levels set 
at P ≤ 0.05. Non-parametric tests were used for compar-
ing knowledge scores, perspectives, and ADR reporting 
practices across the different pharmacist demographics 
(Mann-Whitney U test for 2 groups and Kruskal Wallis for 
more than 2 groups). Exploratory factor analysis (principle 
axis factoring) was performed to simplify the number of 
variables into distinct factors with a non-orthogonal rota-
tion (direct oblimin with Kaiser Normalisation) applied 
after extraction [32]. Negatively worded statements were 
reverse coded and reliabilities of each factor were measured 
by Cronbach’s alpha. Chi square and independent samples t 
test were used to compare the differences in the perceptions 
of pharmacists who have seen and reported at least one ADR 
and those who have seen but not reported any ADR to the 
TGA. Variables showing a p value of less or equal to 0.1 
were included in a logistic regression analysis.
Results
From January to February 2017, a total of 263 surveys were 
collected and 232 were included in the final data analyses 
based on full completion of the survey (Fig. 1). Of the 31 
surveys that were excluded, the respondents only provided 
information on their demographics with minimal completion 
of the questions in the actual survey, and therefore this data 
could not be used for analysis. The demographic details of 
the community pharmacists are summarised in Table 1.
Knowledge
The median knowledge score was 5 out of 10 (interquar-
tile range 4–6, range 1–9). There were no significant differ-
ences in the knowledge scores of pharmacists based on hours 
worked per week, number of years of registration, having 
a professional membership, or highest level of pharmacy 
qualification obtained. However, there was a weak correla-
tion between higher knowledge scores and the longer a phar-
macist was registered (Spearman’s Rho 0.131, P = 0.047).
There were 81.9% (n = 190) of respondents who 
were able to define pharmacovigilance though only 
13.8% (n = 32) of them correctly identified examples of 
an adverse event. Despite the fact that the majority of 
respondents (84.9%, n = 197) knew the type of ADRs 
that the TGA wants healthcare professionals to report, 
only 3.0% (n = 7) of them were able to identify the office 
responsible for the collection and analysis of ADRs at the 
TGA. Almost two thirds of respondents (60.8%, n = 141) 
were able to differentiate between an adverse event and 
an ADR. Conversely, less than half of the respondents 
correctly identified what the TGA considers as a serious 
ADR (8.6%, n = 20), the mode of communication between 
TGA and healthcare professionals (40.5%, n = 94), and the 
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Table 1  Respondent 
demographics
a Professional memberships include Pharmaceutical Society of Australia, Pharmacy Guild of Australia, 
Australian college of Pharmacy, Society of Hospital Pharmacists Australia, and Australian Association of 
Consultant Pharmacy
b Post-graduate degrees include honours, graduate certificate/diploma, masters and doctorate (Ph.D.) in 
pharmacy
Variables Respondents, n = 232 %
State
NSW 126 54.3
QLD 47 20.3
VIC 54 23.3
TAS 5 2.1
Hours worked per week
< 20 h 13 5.6
20–40 h 102 44.0
> 40 h 117 50.4
Years of registration
5 years or less 80 34.5
6–9 years 69 29.7
10 years or more 83 35.8
Professional membershipsa
Yes 125 53.9
No 107 46.1
Highest level of pharmacy qualification
Bachelors 154 66.4
Post-graduateb 78 33.6
Recruitment 
strategies
Facebook page
Flow of 
participants Respondents (n=263)
Final analysis (n=232)
Excluded
Non-compleon of survey (n=31)
Social Media
- PSA early career pharmacists
- Sydney locum pharmacists
- Locum pharmacists Brisbane
- Pharmacist locums – Melbourne
- Locum pharmacists – Tasmania
- Rural pharmacy locums Australia
Australian Journal of Pharmacy 
Discussion Form
Email to community pharmacies 
with a publicly available email 
address
Fig. 1  Flowchart of recruitment of participants from New South Wales, Queensland, Victoria, and Tasmania
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common safety issues involving medicines on the market 
(25.4%, n = 59).
Perceived importance, facilitators and barriers 
of ADR reporting
The factor analysis of the perceptions section yielded a 3 fac-
tor solution based on Eigenvalues of greater than 1 explain-
ing more than half of the total variance (Table 2). The item 
‘I currently have sufficient knowledge and training on how 
to report ADRs’ was removed as the self-reporting of knowl-
edge was considered a separate construct. The following sec-
tion will present the results of each factor separately.
Perceived importance of ADR reporting
Nearly all respondents (97.0%, n = 225) believed that reporting 
ADRs is important for patient care and the majority (93.1%, 
n = 216) felt that they are obliged to report ADRs to the rel-
evant authority, the TGA (Table 3). More than two thirds of 
pharmacists (72.0%, n = 167) also believed that reporting 
ADRs should be mandatory. Most respondents believed that 
pharmacovigilance should be included in the undergraduate 
pharmacy curriculum (95.3%, n = 221) and professional bodies 
should include it in their continuous professional development 
activities (89.7%, n = 207). The factor analysis showed that 
all the above statements had very high loadings with accept-
able reliability (Cronbach’s alpha 0.778) which appropriately 
explains the perceived importance of ADR reporting.
Facilitators of ADR reporting
Having patient information automatically populated from the 
dispensing software into an ADR report ready for submis-
sion was the most popular way to encourage pharmacists to 
report ADRs with 91.8% (n = 213) of respondents agreeing 
with this statement. Other factors such as providing general 
education on pharmacovigilance and setting a reminder in 
the dispensing software were also seen as effective measures 
with 89% (n = 207) and 85% (n = 197) of respondents agree-
ing with these proposals, respectively. These three items also 
had very high factor loadings together with acceptable reli-
ability (Cronbach’s alpha 0.792) and was labelled as facilita-
tors of ADR reporting.
Barriers to ADR reporting
There were 43.5% (n = 101) of respondents who agreed 
with the statement “I don’t have the time to report ADRs 
as part of my professional practice” whilst 29.3% (n = 68) 
Table 2  Pharmacist perspectives towards reporting ADRs—factor analysis
Factor 1 Perceived importance of reporting ADRs. Factor 2 Barriers to reporting ADRs. Factor 3 Facilitators of reporting ADRs
a Was not classified into any factor due to inadequate loading
Highest loadings for a given item is in bold
Item Loadings
Factor 1 Factor 2 Factor 3
Q11. Reporting ADRs is important for patient care 0.590 − 0.138 − 0.348
Q12. Reporting ADRs should be mandatory for community pharmacists 0.542 − 0.254 − 0.226
Q14. Pharmacovigilance should be taught in the undergraduate pharmacy programs at universities 0.629 − 0.099 − 0.300
Q15. Professional bodies (e.g. PSA) should organise workshops or training sessions to cover the importance of 
ADR reporting
0.803 − 0.100 − 0.354
Q18. I have a professional obligation to report ADRs 0.728 − 0.349 − 0.47
Q13. I don’t have the time to report ADRs as part of my professional practice − 0.124 0.603 − 0.129
Q17. I fear that there may be legal repercussions if I report an ADR to the TGA − 0.264 0.427 0.243
Q20. I would be encouraged to report more ADRs if it was remunerated 0.088 0.490 − 0.425
aQ19. There are no results or actions taken based on ADRs that I report − 0.062 0.235 0.017
Q21. I would be encouraged to report more ADRs if there is a reminder in my dispensing software 0.521 0.041 − 0.646
Q22. I would be encouraged to report more ADRs if patient information is automatically populated from the 
dispensing software into an ADR report ready for submission
0.482 − 0.036 − 0.936
Q23. I would be encouraged to report more ADRs if general education is provided on the importance of pharma-
covigilance
0.584 0.059 − 0.618
Eigenvalues 4.017 1.714 1.085
% of variance explained 33.5 14.3 9.0
Total % of variance explained 56.8
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Table 3  Pharmacist perspectives towards reporting ADRs (%)
Question Strongly 
disagree (%)
Disagree 
(%)
Neutral (%) Agree (%) Strongly 
agree (%)
Q11. Reporting ADRs is important for patient care 0.9 0 2.2 30.6 66.4
Q12. Reporting ADRs should be mandatory for community pharmacists 0.9 7.8 19.4 47.0 25.0
Q13. I don’t have the time to report ADRs as part of my professional practice 9.5 19.8 27.2 34.9 8.6
Q14. Pharmacovigilance should be taught in the undergraduate pharmacy 
programs at universities
0.9 0 3.9 52.6 42.7
Q15. Professional bodies (e.g. PSA) should organise workshops or training ses-
sions to cover the importance of ADR reporting
0.4 1.3 8.6 55.2 34.5
Q16. I currently have sufficient knowledge and training on how to report ADRs 6.0 27.2 35.8 26.3 4.7
Q17. I fear that there may be legal repercussions if I report an ADR to the TGA 33.2 51.7 11.2 3.4 0.4
Q18. I have a professional obligation to report ADRs 0.4 0.4 6.0 56.0 37.1
Q19. There are no results or actions taken based on ADRs that I report 6.9 30.6 40.1 20.7 1.7
Q20. I would be encouraged to report more ADRs if it was remunerated 3.0 9.5 22.8 34.9 29.7
Q21. I would be encouraged to report more ADRs if there is a reminder in my 
dispensing software
1.7 3.9 9.5 44.4 40.5
Q22. I would be encouraged to report more ADRs if patient information is 
automatically populated from the dispensing software into an ADR report 
ready for submission
0.4 1.3 6.5 42.2 49.6
Q23. I would be encouraged to report more ADRs if general education is pro-
vided on the importance of pharmacovigilance
0.4 1.3 9.1 56.0 33.2
Table 4  Variables associated 
with adverse drug reaction 
reporting in community 
pharmacists
Variables Adjusted OR (95% CI)
Perceived importance of ADR reporting 1.04 (0.93–1.16)
Enablers of ADR reporting 1.02 (0.85–1.24)
Barriers to ADR reporting 1.43 (1.19–1.71)
Total marks 1.05 (0.83–1.32)
21–40 h worked per week 4.30 (1.22–15.16)
> 40 h worked per week 1.48 (0.81–2.70)
of respondents disagreed. Approximately 65% (n = 150) of 
respondents also agreed that remuneration would encourage 
them to report ADRs and this shows that the current lack of 
remuneration for reporting ADRs in Australia is a substan-
tial barrier. There was also a moderate correlation between 
not having the time to report ADRs and being encouraged to 
report ADRs if reporting was remunerated (Spearman’s Rho 
0.364, P < 0.001). Furthermore, there were 22.4% (n = 52) 
of respondents who agreed with the statement “There are 
no results or actions taken based on ADRs I report”. Over 
84% (n = 197) of respondents also disagreed with the state-
ment “I fear that there may be legal repercussions if I report 
an ADR to the TGA”. The factor analysis showed that the 
items above had high loadings and described the barriers to 
reporting ADRs. However, the reliability of this factor was 
low (Cronbach’s alpha 0.488).
ADR reporting and variables associated 
with reporting practices
Only 35.3% (n = 82) of pharmacists have reported at least 
one ADR to the TGA in the previous 12 months, even 
though 88.4% (n = 205) of pharmacists encountered an ADR 
in a patient and 65.9% (n = 153) record ADRs as part of 
a clinical intervention at least once a month. Independent 
samples t test showed that there was a significant difference 
between pharmacists who have reported ADRs versus those 
who have never reported based on their hours worked per 
week (1.52 vs. 1.33, P = 0.024). However, Chi squared test 
revealed that there was no significant relationship between 
the number of hours worked and the reporting of ADRs 
(P = 0.058). As evident from Table 4, the logistic regression 
showed that the number of hours worked per week was a 
significant predictor for whether pharmacists reported ADRs 
or not (OR 4.32, 95% CI 1.22–15.16). Furthermore, barriers 
to ADR reporting was also a significant predictor of whether 
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pharmacists reported ADRs (OR 1.43, 95% CI 1.19–1.71). 
All other variables assessed were not significant predictors.
Respondents also provided various suggestions that may 
encourage pharmacists to report more ADRs as qualitative 
comments. These includes: making reporting a habit start-
ing within university education, commencing an educational 
advertising campaign in this area, adding a prompt to report 
ADRs during online recording of clinical interventions, 
adding ADR reporting as a separate reimbursable cogni-
tive activity, and receiving feedback on ADR reports that 
pharmacists had made to see what impact the reports had.
Discussion
Underreporting of ADRs is a widespread problem around 
the world and the voluntary nature of reporting is not helping 
the situation [33]. A number of ADR presentations in acute 
care may be attributable to a patient’s current illness and 
association with a suspected drug may not be clear enough to 
encourage prompt reporting [34]. Community pharmacists 
in Australia are well placed to collect, and report ADRs to 
the regulatory authority as they are the publics’ most fre-
quently visited healthcare professional [27]. However, there 
is a clear gap in our understanding of their knowledge and 
perspectives towards ADR reporting with only one third 
of respondents considering themselves knowledgeable and 
trained in ADR reporting. Therefore, this ‘first of its kind’ 
survey development and piloting study was conducted to 
investigate this missing information. The newly developed 
pharmacovigilance survey tool was found to be a reliable 
and valid measure of the knowledge, perspectives and prac-
tices of reporting ADRs in Australia.
We showed that community pharmacists’ knowledge of 
pharmacovigilance in Australia is limited. Knowledge scores 
were not higher in respondents with post-graduate qualifica-
tions or those with more years of experience indicating that 
pharmacists did not receive adequate education as part of 
their continuing professional development. This is an impor-
tant unmet need and is supported by the finding that almost 
all respondents agreed that pharmacovigilance should be 
included into the curricula of undergraduate pharmacy pro-
grams and that professional organisations should organise 
workshops to highlight the importance of reporting ADRs. 
There have been some efforts to draw healthcare professional 
awareness to the importance of reporting ADRs with the 
TGA and the National Prescribing Service recently creating 
2 online continuing education modules in 2014 to explain 
the importance of reporting ADRs and how to build report-
ing into practice [35]. Despite this, there was still no increase 
in the number of ADRs reported to the TGA by healthcare 
professionals in 2016 [11] and therefore, additional activities 
to increase awareness and address reporting barriers must 
be considered.
We found that only 35% of community pharmacists 
have reported at least one ADR to the TGA in the previous 
12 months and this low reporting rate is supported by TGA 
data showing that only 903 ADRs were reported by commu-
nity pharmacists out of a total of approximately 17,000 case 
reports (5.3%) in 2016 [11]. This may be attributed to the 
limited pharmacovigilance knowledge of pharmacists with 
only a third agreeing that they have sufficient knowledge and 
training on this topic. The low ADR reporting rates are also 
consistent with studies conducted across Europe, Asia and 
Africa, which showed reporting rates of between 14 and 44% 
to their respective national ADR reporting centres [18–23]. 
This large variance in ADR reporting rates may be attrib-
uted to the different working environments and challenges 
that community pharmacists face in different countries. For 
example, a study in Jordan showed that 30% of pharmacists 
feared legal liability when reporting ADRs compared to only 
4% in this study [20]. A study in Iran showed that only 26% 
of pharmacists believed reporting ADRs is a professional 
obligation compared to 93% in this study [22]. However, all 
studies concluded that providing education and training in 
pharmacovigilance is essential to improve awareness, knowl-
edge and ADR reporting rates.
Non-reporting community pharmacists indicated that lack 
of time was the most significant barrier to reporting ADRs 
in Australia. This was expected, as community pharmacists 
are now providing a number of professional services such as 
MedsChecks Program, dose administration aids, home medi-
cines reviews, and clinical interventions in addition to their 
traditional role of dispensing and supplying medicines [36]. 
However, we also showed that community pharmacists who 
have reported ADRs to the TGA did not perceive time as a bar-
rier and this suggests that it is the underlying perspectives of 
the individual pharmacist that affects how they allocate time to 
perform ADR reporting as part of their professional practice. 
Despite this, the concern about lack of time for non-reporting 
pharmacists should not be disregarded and existing processes 
for ADR reporting can be further simplified. Therefore, one of 
the priorities to improve ADR reporting rates by community 
pharmacists would be to shorten the time it takes to complete 
the process. This can be achieved by making the reporting 
forms more accessible, electronic, and utilise any auto-pop-
ulation features available from existing information in the 
dispensing software. In June 2014, a pharmacy software ven-
dor Guildlink created an Adverse Events Recording module 
into community pharmacy dispensing software that integrates 
directly into the TGA ADR web service [37]. This allows com-
munity pharmacists to report ADRs directly to the TGA via 
their dispensing software instead of having to manually com-
plete a separate ADR reporting form. By September 2014, 
the TGA received 254 reports from community pharmacists 
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via this GuildLink portal and the number of ADRs reported 
by community pharmacists in the first three quarters of 2014 
was almost as high as the total number of reports received 
from community pharmacists for the entire year in 2013 [38]. 
It suggests these measures to simplify the ADR reporting pro-
cess were well received and further initiatives are required to 
increase the volume of ADRs reported by healthcare profes-
sionals. However, it is also important to highlight that ADR 
reporting rates by pharmacists fell again in 2015 indicating that 
constant reminders are necessary to encourage and maintain 
higher ADR reporting rates.
Limitations and future research
One of the key limitations for this study is that the sample 
size of 375 community pharmacists was not reached, indi-
cating that these results may not be representative of the 
entire group of community pharmacists registered in Aus-
tralia. The number of pharmacists working less than 20 h 
was also significantly under-represented at only 5.6% of our 
sample compared to 13.9% in the wider community pharma-
cist population [30]. Secondly, there is the impact of social 
desirability bias from the pharmacist respondents to consider 
[39]. Community pharmacists may feel guilty for not report-
ing ADRs as often as they should as part of their profes-
sional practice and the ADR reporting frequencies recorded 
in this survey may be inflated. Some pharmacists may have 
provided ‘socially desirable’ responses about their perspec-
tives towards the importance of reporting ADRs. However, 
the use of self-administered anonymised surveys would have 
reduced the impact of this bias.
Further research can be conducted to investigate the per-
spectives of other healthcare professional groups such as 
GPs, nurses, and hospital staff towards reporting ADRs in 
Australia. This may focus on looking at specific interven-
tional strategies that address the barriers towards reporting 
ADRs and investigate the effectiveness of these interven-
tions. Research can be undertaken to examine the impact of 
pharmacovigilance educational programs into changing the 
perspectives, and practice of reporting ADRs. For example, 
if pharmacists were provided with information on why ADR 
reporting is so important, they may change their perspectives 
and allocate more of their time to report ADRs as part of 
their professional practice.
Conclusion
The ADR reporting rate by community pharmacists in Aus-
tralia is low even though the vast majority believe they have 
a professional obligation to report. The most significant 
barrier to reporting ADRs is lack of time and this can be 
addressed by simplifying the current reporting procedures 
and utilising auto-population features from existing soft-
ware. This is reinforced by the fact that the reported barri-
ers and the number of hours worked per week by community 
pharmacists are significant predictors of their rate of ADR 
reporting in Australia.
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Appendix
Pharmacovigilance Survey Tool
Knowledge questions
1. What is the definition of pharmacovigilance?
a) The detection, assessment, understanding, and pre-
vention of adverse reactions*
b) The reporting of adverse reactions
c) The science of improving the safety profile of a 
medicinal product
d) The science of weighing the benefit risk profile of a 
medicinal product
e) I do not know
2. Which of the following is an example of an adverse 
event?
a) A patient taking Drug X was hospitalised for a 
stroke. The hospital doctor believes Drug X did not 
cause the stroke
b) A patient taking Drug X experienced a rash. The 
rash was believed to have been caused by Drug X
c) A patient taking Drug X said it didn’t work for him. 
He did not experience any side effects
d) All of the above*
e) I do not know
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3. What type of adverse reactions does the TGA want 
healthcare professionals to report in Australia?
a) Serious and unexpected adverse reactions
b) Non-serious adverse reactions
c) Expected adverse reactions
d) All adverse reactions regardless of seriousness and 
expectedness*
e) I do not know
4. In Australia, which group at the TGA is currently 
responsible for the collection and monitoring of ADRs
a) Adverse Drug Reaction Advisory Committee 
(ADRAC)
b) Office of Product Review (OPR)
c) Pharmacovigilance and Special Access Branch 
(PSAB)*
d) Australian Drug Evaluation Committee (ADEC)
e) I do not know
5. The TGA accepts ADR reports from:
a) Consumers and patients only
b) Healthcare professionals only
c) Hospital networks only
d) All of the above*
e) I do not know
6. How does the TGA communicate important or new 
ADR information that have been confirmed?
a) TGA Early Warning System – monitoring commu-
nications
b) TGA Medicines Safety Update bulletins*
c) TGA Risk Management plan
d) All of the above
e) I do not know
7. At which stage is the most adverse event information 
collected about a drug?
a) Phase I clinical trials
b) Phase II clinical trials
c) Phase III clinical trials
d) Phase IV clinical trials and post marketing surveil-
lance*
e) I do not know
8. Please consider the following 3 statements. Choose the 
CORRECT answer
I. The terms adverse event and ADR are synonymous 
and can be used interchangeably
II. An adverse event is considered as anything medi-
cally untoward that happens and there does not need 
to be an established causal relationship between the 
adverse event and the drug
III. ADRs are collected during clinical trials, whilst 
adverse events are collected during post marketing 
surveillance activities
a) Only statement I is correct
b) Only statement II is correct*
c) Only statements I and II are correct
d) Only statements II and III are correct
e) I do not know
9. Which of the following scenarios would NOT always be 
considered as a serious adverse event by the TGA?
a) An adverse event that results in hospitalisation
b) An adverse event that is severe*
c) An adverse event that results in congenital anomaly/
birth defect
d) An adverse event that was considered to be serious 
by a healthcare professional
e) I do not know
10. What is the most common safety reason for withdraw-
inga drug from the market?
a) Hepatotoxicity*
b) Cardiotoxicity
c) Carcinogenicity
d) Nephrotoxicity
e) I do not know
*Denotes correct answer at the time of publication
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Perspectives (Likert scale – 5)
11. Reporting ADRs is important for patient care 
          Strongly Disagree                Disagree  Neutral                Agree                Strongly Agree 
12. Reporting ADRs should be mandatory for community pharmacists 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
13. I don’t have the time to report ADRs as part of my professional practice 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
14.  Pharmacovigilance  should be taught in the undergraduate pharmacy programs at universities 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
15. Professional bodies (e.g. Pharmaceutical Society of Australia) should organise workshops or training 
sessions to cover the importance of ADR reporting 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
16. I currently have sufficient knowledge and training on how to report ADRs 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
17. I fear that there may be legal repercussions if I report an ADR to the TGA 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
18. I have a professional obligation to report ADRs 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
19. There are no results or actions taken based on ADRs that I report 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
20. I would be encouraged to report more ADRs if it was: 
Remunerated 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
21. There is a reminder in my dispensing software 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
22. Patient information is automatically populated from the dispensing software into an ADR report ready for 
submission
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
23. General education is provided on the importance of pharmacovigilance 
Strongly Disagree   Disagree  Neutral   Agree                Strongly Agree 
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Pharmacist practice related questions
 24. How often do you see ADRs in patients?
a) At least once a week
b) At least once a month
c) At least once a year
d) Never
25. How often do you record ADRs as part of your clinical 
interventions?
a) At least once a week
b) At least once a month
c) At least once a year
d) Never
 26. What is the most common method that you use to 
report an ADR to TGA?
a) Phone
b) Fax
c) Email
d) TGA ADR blue card
e) TGA online reporting portal
f) I have not reported any ADRs to the TGA 
 27. What is the most common method that you use to 
report an ADR to TGA?
a) Phone
b) Fax
c) Email
d) TGA ADR blue card
e) TGA online reporting portal
f) I have not reported any ADRs to the TGA 
 28. Finally, do you have any suggestions on what would 
encourage you to report more ADRs? (free text field)
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